GlassScriptPhysician profile
Samantha Caines
NPI 1861918054
$1,476.36
in general payments reported to CMS, 2019-2025
25 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $397 · 2022: $246 · 2023: $320 · 2024: $301 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $833.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $395.43 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $231.97 | 2021-2022 | |
| Cvrx, INC. | $149.93 | 2022-2023 | Barostim Neo System |
| Daiichi Sankyo INC. | $84.37 | 2021-2024 | Injectafer |
| United Therapeutics Corporation | $79.23 | 2024-2025 | Tyvaso, Tyvaso |
| Abbott Laboratories | $63.38 | 2021-2024 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Boston Scientific Corporation | $57.92 | 2022-2025 | Varithena Administration Pack |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $51.41 | 2023-2025 | Lifevest |
| Esperion Therapeutics, INC. | $46.22 | 2021 | |
| Pfizer INC. | $46.00 | 2022-2025 | |
| Atricure, INC. | $31.70 | 2024 | |
| Novo Nordisk INC | $30.00 | 2025 | Wegovy |
| Amgen INC. | $26.10 | 2021-2022 | |
| Lundbeck LLC | $22.12 | 2021 | |
| Inspire Medical Systems, INC. | $21.91 | 2025 | Inspire |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $17.50 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $14.59 | 2023 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $14.23 | 2023 | Eliquis |
| Stryker Corporation | $14.10 | 2022 | |
| Altathera Pharmaceuticals LLC | $13.72 | 2023 | Sotalol Hydrochloride |
| Astrazeneca Pharmaceuticals LP | $13.68 | 2025 | Farxiga |
| Actelion Pharmaceuticals US, INC. | $13.65 | 2023 | Opsumit, Uptravi |
| Amryt Pharma Holdings LTD | $13.48 | 2021 | |
| La Jolla Pharmaceutical Company | $12.97 | 2023 | Giapreza |
| Lemaitre Vascular, INC. | $10.75 | 2023 | Artegraft Vascular Graft |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Caines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.